GlassScriptPhysician profile
Roshani Patel
NPI 1396912572
$3,439.51
in general payments reported to CMS, 2019-2025
11 companies · $2,914 in 2025
The $2,914 reported for 2025 was more than what 85% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $85.01 · 2024: $441 · 2025: $2,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,779 · Food and Beverage: $560 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,779.33 |
| Food and Beverage | $560.19 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $2,779.33 | 2025 | Micromatrix, Cytal |
| Endomagnetics LTD | $223.24 | 2024 | Magseed, Magtrace |
| Abbvie INC. | $140.54 | 2024 | |
| Gilead Sciences, INC. | $135.50 | 2024-2025 | Trodelvy |
| Samsung Hme America, INC. | $45.00 | 2023 | |
| Kci USA, INC. | $23.49 | 2023 | V.A.C. Veraflo, Prevena Restor Bellaform |
| Astrazeneca Pharmaceuticals LP | $21.12 | 2024 | Lynparza |
| Davol INC. | $19.15 | 2024 | Arista Ah Flexitip |
| Merck Sharp & Dohme LLC | $18.75 | 2024 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $16.87 | 2025 | |
| Tactile Systems Technology INC | $16.52 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshani Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.